이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms (ATLAS)

2026년 11월 3일 업데이트: Biogen

슈퍼옥사이드 디스뮤타제 1 돌연변이가 확인된 임상적으로 증상이 없는 성인에서 시작된 BIIB067 평가를 위한 종단적 자연사 도입 및 공개 라벨 확장을 포함하는 3상 무작위, 위약 대조 시험

In this study, researchers will learn more about the effects of a drug called tofersen, also known as BIIB067 and QALSODY®, in adults with amyotrophic lateral sclerosis (ALS) who have a superoxide dismutase 1 (SOD1) gene mutation.

One of the causes of ALS is a change (or mutation) in the SOD1 gene, which causes abnormal SOD1 protein to be made. This abnormal protein can cause the motor neurons in people with ALS to break down and die. When neurons are damaged, they release a protein called neurofilament light chain, also known as NfL. Previous studies have shown that NfL levels are higher in people with SOD1-ALS, even before any ALS symptoms appear.

In this study, researchers will look at the effect of tofersen treatment in the earlier stages of the disease, even before ALS symptoms appear. Researchers believe that giving tofersen to patients as early as possible may slow the onset of ALS symptoms and the progression of the disease.

This study will have 4 parts. In Part A, participants will have their health monitored and NfL levels tested on a monthly basis, but they will not receive any study drug. Tofersen or placebo will be given to participants in Parts B, while all participants will receive tofersen in Parts C and D.

The main question that researchers want to answer is:

• How long does it take for ALS symptoms to appear?

Researchers will also learn more about:

  • How many participants develop ALS symptoms within 24 months of the start of Part B
  • Changes in participants' ability to perform their daily activities
  • Changes in participants' ability to breathe
  • How many participants die or need long-term breathing support
  • Changes in NfL levels in the blood
  • Changes in SOD1 protein levels in the fluid around the brain and spinal cord
  • How many participants have adverse events or serious adverse events. Adverse events are health problems that may or may not be caused by the study drug.

The study will be done as follows:

  • Participants will first be screened to check if they can join the study. The screening period will be up to 6 weeks. Participants will join the study only after reading and signing an informed consent form, also known as an ICF.
  • In Part A, participants with presymptomatic ALS will not get any study drugs. Researchers will check the levels of NfL in their blood. Participants will be closely checked for any signs or symptoms of ALS.
  • Once a participant's NfL levels rise to a certain amount, they will move onto Part B.
  • In Part B, participants will be randomly assigned to get either tofersen or a placebo. Neither participants nor researchers will know who gets tofersen or the placebo during Part B. A placebo looks like the study drug but contains no medicine.
  • Participants will get the first 3 doses of tofersen once every 14 days. Afterwards, they will continue getting maintenance doses every 28 days.
  • All doses will be given through an intrathecal (IT) injection done through a lumbar puncture procedure. This involves injecting the drug into the fluid surrounding the spinal cord in the lower back.
  • Participants who develop ALS symptoms during Part B will move to Part C to receive tofersen.
  • Participants who develop ALS symptoms during Part A will move to Part D to receive tofersen.
  • In both Parts C and D, participants will know they are receiving tofersen.
  • Throughout the study, doctors will measure any changes to the participants' function and quality of life using different questionnaires. Doctors will also take blood and urine samples. They will also check the participants' overall health and ask how they are feeling.
  • Participants will have a follow-up visit 28 days after their last dose of study drug.
  • Participants will be in this study for up to about 6.5 years.

연구 개요

상세 설명

The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability of tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest ALS.

연구 유형

중재적

등록 (실제)

158

단계

  • 3단계

확장된 액세스

승인됨 대중에게 판매합니다. 확장 액세스 기록을 참조하세요.

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Seoul, 대한민국, 04763
        • Hanyang University Seoul Hospital
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, 독일, 89081
        • Universitaetsklinikum Ulm
    • Lower Saxony
      • Hanover, Lower Saxony, 독일, 30625
        • Medizinische Hochschule Hannover
    • Arizona
      • Scottsdale, Arizona, 미국, 85258
        • HonorHealth Neurology
    • California
      • La Jolla, California, 미국, 92093-0949
        • University of California San Diego Medical Center
      • San Francisco, California, 미국, 94107
        • California Pacific Medical Center Research Institute
    • Florida
      • Fort Lauderdale, Florida, 미국, 33308
        • Holy Cross Hospital
      • Miami, Florida, 미국, 33136
        • University of Miami School of Medicine
    • Georgia
      • Atlanta, Georgia, 미국, 30322-4200
        • The Emory Clinic
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • Northwestern Medicine
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Charlestown, Massachusetts, 미국, 02129
        • Massachusetts General Hospital, MA
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • Washington University School of Medicine
    • New York
      • New York, New York, 미국, 10032
        • Columbia University Medical center
    • Texas
      • Austin, Texas, 미국, 78756
        • Austin Neuromuscular Center
      • Leuven, 벨기에, 3000
        • UZ Leuven
      • São Paulo, 브라질, 04038-002
        • PSEG Centro de Pesquisa Clinica
    • São Paulo
      • São Paulo, São Paulo, 브라질, 04037-002
        • Hospital Sao Paulo
      • Umeå, 스웨덴, 90185
        • Norrlands Universitetssjukhus
    • Västerbotten County
      • Umeå, Västerbotten County, 스웨덴, 90185
        • University Hospital of Umea
      • Valencia, 스페인, 46026
        • Hospital Universitari i Politecnic La Fe
    • South Yorkshire
      • Sheffield, South Yorkshire, 영국, S10 2RX
        • University of Sheffield
      • Torino, 이탈리아, 10124
        • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, 일본, 890-8520
        • Kagoshima University Hospital
    • Tokyo-To
      • Bunkyō City, Tokyo-To, 일본, 113-8655
        • University of Tokyo Hospital
    • Alberta
      • Calgary, Alberta, 캐나다, T2N4Z6
        • University of Calgary
    • Ontario
      • Toronto, Ontario, 캐나다, M4N 3M5
        • Sunnybrook Health Sciences Centre
    • Quebec
      • Montreal, Quebec, 캐나다, H4A 3T2
        • Genge Partners
      • Warsaw, 폴란드, 01-684
        • Centrum Medyczne NeuroProtect
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, 폴란드, 01-684
        • NeuroProtect Sp. z o.o.
    • Paris
      • Paris, Paris, 프랑스, 75651
        • Groupe Hospitalier Pitie-Salpetriere
    • New South Wales
      • Macquarie Park, New South Wales, 호주, 2109
        • Macquarie University Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Key Part A Inclusion Criteria:

  • Participants should have a protocol-defined rapidly progressive SOD1 mutation, confirmed by a central reader, or a SOD1 mutation that is approved for inclusion by an external mutation adjudication committee.
  • Participants with plasma NfL level less than the protocol-defined threshold.
  • Participants who are clinically presymptomatic for ALS (i.e., must not have clinically manifest ALS).

Key Part A Exclusion Criteria:

  • History or positive test result at screening for human immunodeficiency virus (HIV). The requirement for testing at Screening may be omitted if it is not permitted by local regulations.

  • Current hepatitis C infection [defined as positive Hepatitis C Virus (HCV) antibody and detectable HCV ribonucleic acid (RNA)]. Participants with positive HCV antibody and undetectable HCV RNA are eligible to participate in the study (United States Centers for Disease Control and Prevention).

  • Current hepatitis B infection (defined as positive for hepatitis B surface antigen (HBsAg) and/or anti-Hepatitis B Core antibody (HBc)). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-hepatitis B surface antibody (HBs) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti- HBs) are eligible to participate in the study.

  • History of systemic hypersensitivity reaction to tofersen, the excipients contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study.

  • History of confounding neuromuscular or neurological disorder that is expected to have a progressive (i.e., worsening) course during the study, and/or is expected to be associated with elevations in NF, in the opinion of the Investigator.

  • Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that if not managed optimally could place a participant at an increased risk for intraoperative or postoperative bleeding.

  • Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression

    ≤ 90 days of screening, which in the opinion of the Investigator would interfere with the study procedures.

  • Treatment with riluzole, edaravone, and/or sodium phenylbutyrate/taurursodiol (also known as ursodoxicoltaurine). If the participant has been on riluzole, edaravone, and/or sodium phenylbutyrate/taurursodiol, the medication(s) must be discontinued for at least 5 half-lives prior to Screening.

  • Use of off-label treatments for ALS.

  • Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed.

  • Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication (e.g., clopidogrel) that cannot be safely continued or held for a Lumbar Puncture (LP) procedure, if necessary, according to local or institutional guidelines and/or Investigator determination.

  • Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment, biological agent, device, or approved therapy for investigational use. Participation in a noninterventional study focused on ALS natural history may be allowed at the discretion of the Investigator.

NOTE: Other protocol defined Inclusion/Exclusion criteria will apply.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
간섭 없음: Part A: Natural History Run-in

Participants enrolled in Part A will undergo blood draws approximately once every 28 days to assess NfL levels.

실험적: Part B: Randomized, Double-Blind, Placebo-Controlled

Participants from Part A who meet the protocol-defined NfL threshold and remain presymptomatic may be eligible to participate in Part B. During Part B, participants will receive tofersen 100 milligrams (mg) or placebo via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to approximately 5.6 years.

Administered as specified in the treatment arm

Administered as specified in the treatment arm

다른 이름들:
  • BIIB067
  • 칼소디
실험적: Part C: Open-Label Extension

Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive tofersen 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter up to the final maintenance dose visit. Participants who received tofersen during Part B will receive tofersen 100 mg on Days 1, 29, and every 28 days thereafter up to the final maintenance dose visit, with a dose of placebo on Day 15 to maintain the study blind. The combined duration of Part B and Part C is up to approximately 5.6 years.

Administered as specified in the treatment arm

Administered as specified in the treatment arm

다른 이름들:
  • BIIB067
  • 칼소디
실험적: Part D: Open-Label Treatment

Participants from Part A who develop clinically manifest ALS prior to randomization in Part B may be eligible to participate in Part D. During Part D, participants will receive tofersen 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.

Administered as specified in the treatment arm

다른 이름들:
  • BIIB067
  • 칼소디

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Part B: Time to Emergence of Clinically Manifest ALS
기간: Up to 5.6 years
Up to 5.6 years

2차 결과 측정

결과 측정
측정값 설명
기간
파트 B 및 C: 파트 B 기준선의 24개월 이내에 임상적으로 ALS가 나타난 참가자의 비율
기간: 최대 24개월
최대 24개월
파트 B 및 C: 예측된 느린 폐활량(SVC) 비율의 기준선 대비 변화
기간: 최대 5.6년
최대 5.6년
파트 B 및 C: 사망까지의 시간 분석을 기준으로 결과가 사망인 참가자의 비율
기간: 최대 5.6년
최대 5.6년
파트 B, C 및 D: 치료 기간 동안 부작용(AE) 및 심각한 부작용(SAE)이 발생한 참가자 수
기간: 파트 B 및 C: 최대 5.6년, 파트 D: 최대 2년
파트 B 및 C: 최대 5.6년, 파트 D: 최대 2년
파트 B, C 및 D: 혈장 NfL 농도의 기준선 대비 변화
기간: 파트 B 및 C: 최대 5.6년, 파트 D: 최대 2년
파트 B 및 C: 최대 5.6년, 파트 D: 최대 2년
파트 B, C 및 D: 총 뇌척수액(CSF) SOD1 농도의 변화
기간: 파트 B 및 C: 최대 5.6년, 파트 D: 최대 2년
파트 B 및 C: 최대 5.6년, 파트 D: 최대 2년
Parts B and C: Change in ALS Functional Rating Scale (ALSFRS-R) Total Score
기간: Up to 5.6 years

The ALSFRS-R measures 4 functional domains: respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 to 4, for a total possible score of 48, with higher scores representing better function.

Up to 5.6 years
Parts B and C: Percentage of Participants with Outcome as Death or Permanent Ventilation Based on Time to Death or Permanent Ventilation Analysis
기간: Up to 5.6 years

Permanent ventilation is defined as ≥22 hours of invasive or non-invasive mechanical ventilation per day for ≥21 consecutive days.

Up to 5.6 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Medical Director, Biogen

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 5월 17일

기본 완료 (추정된)

2027년 8월 7일

연구 완료 (추정된)

2028년 5월 25일

연구 등록 날짜

최초 제출

2021년 4월 20일

QC 기준을 충족하는 최초 제출

2021년 4월 20일

처음 게시됨 (실제)

2021년 4월 23일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 233AS303
  • 2023 (미국 NIH 보조금/계약)
  • 2023-505641-12 (기타 식별자: EU Trial (CTIS) Number)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다